Larissa A. Wenning
Department of Drug Metabolism
Merck Research Laboratories
a division of Merck & Co.
Inc., Whitehouse Station
USA
Name/email consistency: high
- Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Wenning, L.A., Petry, A.S., Kost, J.T., Jin, B., Breidinger, S.A., DeLepeleire, I., Carlini, E.J., Young, S., Rushmore, T., Wagner, F., Lunde, N.M., Bieberdorf, F., Greenberg, H., Stone, J.A., Wagner, J.A., Iwamoto, M. Clin. Pharmacol. Ther. (2009)
- Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Wenning, L.A., Hanley, W.D., Brainard, D.M., Petry, A.S., Ghosh, K., Jin, B., Mangin, E., Marbury, T.C., Berg, J.K., Chodakewitz, J.A., Stone, J.A., Gottesdiener, K.M., Wagner, J.A., Iwamoto, M. Antimicrob. Agents Chemother. (2009)
- Lack of a significant drug interaction between raltegravir and tenofovir. Wenning, L.A., Friedman, E.J., Kost, J.T., Breidinger, S.A., Stek, J.E., Lasseter, K.C., Gottesdiener, K.M., Chen, J., Teppler, H., Wagner, J.A., Stone, J.A., Iwamoto, M. Antimicrob. Agents Chemother. (2008)
- Pharmacokinetics of famotidine in infants. Wenning, L.A., Murphy, M.G., James, L.P., Blumer, J.L., Marshall, J.D., Baier, J., Scheimann, A.O., Panebianco, D.L., Zhong, L., Eisenhandler, R., Yeh, K.C., Kearns, G.L. Clin. Pharmacokinet (2005)
